Search academic texts

Information × Registration Number 0220U000431, 0118U003022 , R & D reports Title Optimization of maintenance therapy with intravenous immunoglobulins of patients with B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma/ popup.stage_title Head Tymchenko Anatoliy Serhiyovych, Registration Date 11-02-2020 Organization State Institution "Institute of Haematology and Transfusiology of NAMS of Ukraine" popup.description2 Object of research - the patients with B-cell chronic lymphocytic leukemia/ small lymphocyte lymphoma (B-CLL/SLL), blood and blood serum of patients with B-CLL /SLL. Aim of of research - to determine the criteria for the appointment of substitution therapy with immunoglobulins for intravenous administration (IVIG) to patients with B-CLL/SLL in the dynamics of chemotherapy (CT). Research methods - general clinical, morphological, immunological, biochemical, instrumental, statistical. 57 patients with B-CLL/SLL were examined: 30 patients with B-CLL, 27 patients with B-cell SLL. The study group consisted of patients who were first diagnosed with B-CLL/SLL (primary patients, n = 18) and patients with B-CLL/SLL who received pre-chemotherapy (HT) but were admitted to the study group after the break in treatment, before the start of the next course of HT (n = 39). The study of general clinical parameters, the content of the main classes of immunoglobulins (IgG, IgA, IgM), the fractional composition of serum proteins and electrocardiogram, systemic hemodynamics and cardiohemodynamics before the start of HT (baseline). In patients with B-CLL/SLL, a wide range of discrepancies between the initial indicators of the content of major Ig classes in serum (from hypo- to hyperglobulinemia) was detected. The analysis of the research results substantiates the need for the use in the replacement therapy of patients with B-CLL/SLL replacement IVIG therapy, as well as for the support of cardiac activity - drugs of metabolic action. The criteria for prescribing IVIG replacement therapy in patients with B-CLL/SLL may be: 1) a decrease in serum IgG content below 6.0 g/l; 2) the occurrence of a patient with severe (WHO criteria) or recurrent infectious-inflammatory complication (IIC); 3) ineffective antibiotic therapy of IIC. Branch of application - medicine. Medical and social effect. The medicine. Product Description popup.authors Вергун Л.Ю. Лановенко І.І. Сівкович С.О. Сергутіна С.Ю. popup.nrat_date 2020-04-02 Close